Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agenus Inc (AGEN)

Agenus Inc (AGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 152,056
  • Shares Outstanding, K 38,398
  • Annual Sales, $ 114,200 K
  • Annual Income, $ 120 K
  • EBIT $ -20 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.60
  • Price/Sales 1.50
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 111.64% (+1.97%)
  • Historical Volatility 101.82%
  • IV Percentile 31%
  • IV Rank 6.25%
  • IV High 524.17% on 02/06/26
  • IV Low 84.12% on 08/04/25
  • Expected Move (DTE 3) 0.51 (12.29%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 1,075
  • Volume Avg (30-Day) 432
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 6,995
  • Open Int (30-Day) 5,171
  • Expected Range 3.64 to 4.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.95
  • Number of Estimates 2
  • High Estimate $2.10
  • Low Estimate $1.80
  • Prior Year $-1.03
  • Growth Rate Est. (year over year) +289.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.92 +42.12%
on 03/16/26
4.67 -11.13%
on 04/10/26
+1.05 (+33.87%)
since 03/13/26
3-Month
2.71 +53.14%
on 02/05/26
4.87 -14.78%
on 01/14/26
-0.46 (-9.98%)
since 01/13/26
52-Week
1.60 +159.38%
on 04/16/25
7.34 -43.46%
on 07/11/25
+2.45 (+144.12%)
since 04/11/25

Most Recent Stories

More News
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Study highlights novel multi-mechanistic immunotherapy combination in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing, and durability of...

AGEN : 4.15 (+4.80%)
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer Cases Colorectal...

AGEN : 4.15 (+4.80%)
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Webcast on Tuesday, March 31, 2026, at 4:30 p.m. ET

AGEN : 4.15 (+4.80%)
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and reduce use of cytotoxic chemotherapy

AGEN : 4.15 (+4.80%)
Agenus: Q4 Earnings Snapshot

Agenus: Q4 Earnings Snapshot

AGEN : 4.15 (+4.80%)
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

Early access programs expand globally: 200+ physician inquiries across 30+ countries; $4.2M in initial program revenue recognized CRC leads BOT+BAL...

AGEN : 4.15 (+4.80%)
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

Work orders for key CMC and production activities activate first contingent payment as global demand expands across clinical and paid compassionate access programs

AGEN : 4.15 (+4.80%)
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

Agenus Inc. (“Agenus”) (Nasdaq: AGEN ), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before...

AGEN : 4.15 (+4.80%)
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

Integrated analysis of systemic inflammation and tumor immune features identifies biologically distinct patient subgroups with differential survival outcomes, outperforming conventional biomarkers

AGEN : 4.15 (+4.80%)
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

Agenus Inc . ( Nasdaq: AGEN ), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program...

AGEN : 4.15 (+4.80%)

Business Summary

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's...

See More

Key Turning Points

3rd Resistance Point 4.74
2nd Resistance Point 4.52
1st Resistance Point 4.34
Last Price 4.15
1st Support Level 3.93
2nd Support Level 3.71
3rd Support Level 3.53

See More

52-Week High 7.34
Fibonacci 61.8% 5.15
Fibonacci 50% 4.47
Last Price 4.15
Fibonacci 38.2% 3.79
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.